Alto Neuroscience shares are trading lower. The company announced the initiation of a Phase 2b randomized placebo-controlled trial of ALTO-207 in treatment-resistant depression.

Benzinga Newsdesk www.benzinga.com Neutral 58.7%

Neg 0% Neu 58.7% Pos 0%

Comments

No comments yet. Be the first!